Zhi Tong Cai Jing·2025-10-13 08:46Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration certificate of Fumaric Acid Bisoprolol Tablets, enhancing its cardiovascular product line and providing more options for clinical medication [1] Company Summary - The approval of Fumaric Acid Bisoprolol Tablets enriches the company's cardiovascular product offerings [1] - This development indicates the company's commitment to expanding its portfolio in the cardiovascular sector [1] Industry Summary - The approval reflects ongoing regulatory support for new pharmaceutical products in the cardiovascular market [1] - The introduction of new medications can lead to increased competition and innovation within the cardiovascular treatment landscape [1]